Methadone and Rheumatoid Arthritis: Potential Risks & Considerations

Patients with rheumatoid arthritis (RA) who are prescribed methadone—whether for opioid use disorder or chronic pain—should discuss potential interactions with their rheumatologist and prescribing clinician. Methadone can exacerbate certain RA-related complications.

Key Risks to Discuss with Your Doctor

1. Gastrointestinal Side Effects

Methadone commonly causes nausea, vomiting, and constipation. RA patients may already experience GI issues from NSAIDs, corticosteroids, or the disease itself, making these side effects more severe and harder to manage.

2. Accelerated Bone Loss

Both RA and long-term methadone use are independently associated with reduced bone mineral density. Combined, they may significantly increase fracture risk, especially in postmenopausal women and older adults.

3. Immune Suppression and Infection Risk

Methadone has immunomodulatory effects that can suppress immune function. RA patients often take disease-modifying antirheumatic drugs (DMARDs) or biologics that also affect immunity, potentially compounding infection susceptibility.

Clinical Decision-Making

The decision to continue, adjust, or discontinue methadone requires weighing these risks against its benefits (pain control, OUD stability). Alternatives like buprenorphine may have a more favorable bone and immune profile. Regular monitoring of bone density, GI symptoms, and infection markers is essential.

Never stop methadone abruptly. Any medication changes must be supervised by your healthcare team to avoid withdrawal or disease flare.